CTVA Corteva
Q3 2025 10-Q
Corteva (CTVA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Management Discussion & Analysis
- • Revenue and YoY change not disclosed explicitly in provided text
- • Operating cash flow improved to $(941) million for 9 months ended Sept 30, 2025 vs $(1,871) million for same period in 2024
Risk Factors
- • New regulatory risk from recent funding and staff cuts at EPA, USDA, FDA, HHS plus current federal government shutdown impacting timely approvals
- • Updated material regulatory risk: reliance on Coordinated Framework for Biotechnology involving USDA, FDA, EPA authorities for seeds and pesticides
Quarterly Financial SummaryXBRL
Revenue
$2.6B
▲ +12.6% YoY▼ -59.4% QoQ
Net Income
-$320M
▲ +38.9% YoY▼ -124.4% QoQ
Net Margin
-12.2%
▲ +1030bp YoY▼ -3258bp QoQ
ROE
-1.3%
Total Assets
$42.2B
EPS (Diluted)
$-0.46
▲ +38.7% YoY▼ -124.0% QoQ
Operating Cash Flow
$193M
▲ +48.5% YoY▼ -79.6% QoQ
Source: XBRL data from Corteva Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Corteva Quarterly Reports
Get deeper insights on Corteva
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.